TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23967634
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Deanxit, 1 tablet after getting up and after lunch)
Study: 23967634
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (Shugan Jianwei Anshen Decoction, 1 dose a day)
Study: 18641208
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea consumption (4 cups or 960 mL per day)
Study: 14519794
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement capsule
Study: 14519794
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement tablet
Study: 10896881
Drug: Loxiglumide (CCK-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (CCK-A antagonist)
Study: 1613678
Drug: Nimodipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (4 x 60 mg)
Study: 31238972
Drug: Specific acupressure
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific acupressure (self-administered on five specific acupressure points, 1 min for each point, twice a day for 4 weeks)
Study: 31238972
Drug: Non-specific acupressure
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific acupressure (self-administered on five non-specific acupressure points, 1 min for each point, twice a day for 4 weeks)
Study: 26218933
Drug: ESI (epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESI (epidural steroid injections)
Study: 23834353
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low molecular weight heparin (LMWH) and prednisolone
Study: 23834353
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) alone
Study: 31277722
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs
Study: 16888270
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA), 100 mg, administered as 14 daily suppositories starting within 12 hours after aneurysm treatment.
Study: 16888270
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered as 14 daily suppositories starting within 12 hours after aneurysm treatment.
Study: 25122038
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg, over 40 min)
Study: 23822578
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor‐based triple therapy
Study: 21373300
Drug: Fascia-iliaca block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia-iliaca block with bupivacaine and parenteral saline injection (Group A)
Study: 21373300
Drug: IV NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV NSAID injection with fascia-iliaca block (Group B)
Study: 18422393
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel (dual antiplatelet therapy)
Study: 18422393
Drug: Clopidogrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel therapy duration
Study: 18422393
Drug: Resistance to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance to aspirin and clopidogrel
Study: 16634993
Drug: Glucerna SR
Normalized name: GLUCERNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucerna SR 323 ml
Study: 16634993
Drug: Ensure high
Normalized name: Ensure High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensure high calcium 315 ml
Study: 16634993
Drug: Glucose 75
Normalized name: glucose 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 75 g
Study: 10854861
Drug: LMWH (enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH (enoxaparin sodium, 40 mg daily) + low-dose aspirin (100 mg daily) in the first trimester (group 1, n=14)
Study: 10854861
Drug: LMWH (enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH (enoxaparin sodium, 40 mg daily) + low-dose aspirin (100 mg daily) in the second trimester (group 2, n=17)
Study: 10854861
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin alone (group 3, n=15)
Study: 8227478
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg methylprednisolone (Medrol Tablets)
Study: 8227478
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg methylprednisolone (Medrol Tablets)
Study: 8227478
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg methylprednisolone (placebo)
Study: 3541502
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg levothyroxine daily
Study: 3541502
Drug: Routine thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine thyroxine treatment
Study: 31350962
Drug: Gonadotropin, GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin, GnRH antagonist, and GH from the eighth day of the cycle for about 5 days (n = 34)
Study: 31350962
Drug: Gonadotropin, GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin, GnRH antagonist, and GH from the third day of the previous cycle for about 20 days (n = 32)
Study: 31350962
Drug: Gonadotropin, GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin, GnRH antagonist, and placebo from the eighth day of the cycle for about 5 days (n = 26)
Study: 26933848
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg preoperatively)
Study: 22545014
Drug: Polymerized collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymerized collagen (2 mL, 6 intraarticular injections over 3 months)
Study: 22545014
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL, 6 intraarticular injections over 3 months)
Study: 20682030
Drug: Singing classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singing classes (6-week course, twice weekly)
Study: 1577045
Drug: Gallopamil 100
Normalized name: gallopamil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 100 mg b.i.d.
Study: 1577045
Drug: Gallopamil 100
Normalized name: gallopamil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 100 mg o.d.
Study: 4063326
Drug: 20-50 g
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-50 g Palatinit/d
Study: 31733785
Drug: Lumbosacral orthosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbosacral orthosis (LSO) with routine physical therapy
Study: 30652982
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy alone
Study: 8541200
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution as placebo (n = 17)
Study: 1791015
Drug: Aminophylline Tablets
Normalized name: Aminophylline Tablets
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline Tablets
Study: 27781255
Drug: Less than
Normalized name: IgA less than or equal to 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less than 3 months treatment group
Study: 27781255
Drug: More than
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More than 3 months treatment group
Study: 18065143
Drug: Interferon 1-b
Normalized name: Interferon gamma 1-b
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon 1-b injections
Study: 15741226
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy (control)
Study: 8746390
Drug: Non-drug treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug treatments
Study: 8746390
Drug: Drugs (general)
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs (general)
Study: 8746390
Drug: Benzodiazepines, antidepressants,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines, antidepressants, and other substances
Study: 761539
Drug: Proglumide (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumide (1200 mg daily)
Study: 761539
Drug: Magnesium tricilicate
Normalized name: Magnesium Trisilicate
DrugBank: Magnesium trisilicate (DB09281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium tricilicate (1320 mg daily, active placebo)
Study: 21942655
Drug: DHEA 10
Normalized name: calcium carbonate 118 MG (calcium 47 MG) / DHEA 10 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 10 mg daily
Study: 21942655
Drug: HRT (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (1 mg estradiol + 5 mg dihydrogesterone)
Study: 11295026
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (800 microg folic acid, 6 microg vitamin B12, 10 mg vitamin B6)
Study: 11295026
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (160 microg folic acid, no vitamin B12, 10 mg vitamin B6)
Study: 9399608
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD 246 mg
Study: 7703633
Drug: TCM-WM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM-WM therapy
Study: 25636669
Drug: Bilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral injection of technetium-99m macroaggregated albumin (37 MBq/1 mCi per injection)
Study: 25636669
Drug: Unilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral injection of technetium-99m macroaggregated albumin (37 MBq/1 mCi per injection)
Study: 19900212
Drug: Non-prostaglandin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-prostaglandin therapy (non-PGs)
Study: 19900212
Drug: Latanoprost and
Normalized name: latanoprost and netarsudil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost and Non-prostaglandin therapy (non-PGs)
Study: 15019894
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg once daily for 3 weeks before and 6 weeks after electrical cardioversion
Study: 15019894
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug in addition to standard therapy
Study: 8221559
Drug: Cisplatin-epidoxorubicin-cyclophosphamide (CEP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-epidoxorubicin-cyclophosphamide (CEP) chemotherapy alone
Study: 24749354
Drug: Domestically produced
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestically produced Salbutamol Sulfate Aerosol MDI (200 microg single-dose)
Study: 24749354
Drug: Imported Salbutamol
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported Salbutamol Sulfate Aerosol MDI (200 microg single-dose)
Study: 15966702
Drug: Buccal bioadhesive
Normalized name: urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal bioadhesive nystatin tablet (100,000 IU per tablet) applied daily
Study: 15966702
Drug: Conventional local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional local cleaning with oral nystatin suspension on a brush
Study: 15966702
Drug: No antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimicrobial agents (Control group)
Study: 9445494
Drug: Stavudine (d4T)
Normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) 1 mg/kg orally every 12 hours, maximum 40 mg orally every 12 hours
Study: 9445494
Drug: Zidovudine (ZDV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (ZDV, AZT) 180 mg/m2 orally every 6 hours, maximum 200 mg orally every 6 hours
Study: 7599909
Drug: Dipyrone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (1 g, 3 times/day for 2 days, followed by twice 1 g on day 3)
Study: 7599909
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg, 3 times/day for 2 days, followed by twice 50 mg on day 3)
Study: 2369315
Drug: Fluorouracil therapy
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil therapy (500 mg/m2 per day) by portal vein infusion for 7 days
Study: 2369315
Drug: Fluorouracil therapy
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil therapy
Study: 327057
Drug: Combined doses
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined doses of Fenfluramine and Dextroamphetamine
Study: 31895437
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride for 8 weeks
Study: 28126706
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Sertraline and Placebo)
Study: 31511044
Drug: Leucine-enriched essential
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-enriched essential amino acid (L-EAA) supplementation (5 g L-EAA five times per day for up to 14 days)
Study: 28045286
Drug: panic‐focused psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: panic‐focused psychodynamic psychotherapy, cognitive‐behavioral therapy, or applied relaxation therapy (24 twice‐weekly sessions)
Study: 21266669
Drug: Insulin immunodepletion
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin immunodepletion
Study: 19860922
Drug: Phase 2
Normalized name: Premphase 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 white bean extract (powder) at 3000 mg
Study: 19860922
Drug: Phase 2
Normalized name: Premphase 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 white bean extract (capsule) at 2000 mg
Study: 19860922
Drug: Phase 2
Normalized name: Premphase 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 white bean extract (capsule) at 3000 mg
Study: 19860922
Drug: Phase 2
Normalized name: Premphase 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 white bean extract (powder) at 1500 mg
Study: 19860922
Drug: Phase 2
Normalized name: Premphase 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 white bean extract (powder) at 2000 mg
Study: 15217941
Drug: S-1 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 with food (35 mg/m2)
Study: 15217941
Drug: S-1 without
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 without food (35 mg/m2)
Study: 11209118
Drug: Itraconazole (pulse)
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole (pulse) 200 mg twice a day for 1 week, given for 3 pulses
Study: 8067598
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of fluticasone propionate once daily
Study: 8067598
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of fluticasone propionate twice daily
Study: 2897912
Drug: Pancuronium (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (single bolus 0.95 mg kg‐1)
Study: 2897912
Drug: Atracurium (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (single bolus 0.53 mg kg‐1)
Study: 2897912
Drug: Vecuronium (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (single bolus 0.07 mg kg‐1)
Study: 2897912
Drug: Pancuronium (divided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (divided doses 0.15 mg kg‐1, 3 min before 0.08 mg kg‐1)
Study: 2897912
Drug: Atracurium (divided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (divided doses 0.07 mg kg‐1, 3 min before 0.46 mg kg‐1)
Study: 2897912
Drug: Vecuronium (divided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (divided doses 0.01 mg kg‐1, 3 min before 0.06 mg kg‐1)
Study: 1093330
Drug: Sch 1000
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sch 1000 (Atrovent) 0.02 mg
Study: 1093330
Drug: Sch 1000
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sch 1000 (Atrovent) 0.08 mg
Study: 26109589
Drug: apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: apixaban (5 mg twice daily)
Study: 23886150
Drug: CIK cell
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK cell therapy (5 courses over 18 months)
Study: 23886150
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no CIK cell therapy)
Study: 22779193
Drug: Naoxintong capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naoxintong capsule
Study: 22779193
Drug: Tongxinluo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo capsule (Control)
Study: 11380463
Drug: Sequential ADE
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential ADE (cytarabine, daunorubicin, etoposide)
Study: 11380463
Drug: Sequential ADE
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential ADE
Study: 8536027
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pethidine (i. art.) in 50 ml saline
Study: 8536027
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pethidine + 200 micrograms adrenaline (i. art.) in 50 ml saline
Study: 8536027
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg prilocaine + 200 micrograms adrenaline (i. art.) in a volume of 50 ml
Study: 3691607
Drug: Acute AMI
Normalized name: ephedrine sulfate / hydroxyzine hydrochloride / theophylline Oral Tablet [Ami-rax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute AMI 50 mg
Study: 27272084
Drug: Face cream
Normalized name: NAIR FACE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face cream containing 4-Hexyl-1, 3-phenylenediol and ascorbic acid-2 glucoside
Study: 16160867
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (0.4 IU/kg)
Study: 16160867
Drug: Insulin ultralente
Normalized name: INSULIN ULTRALENTE BEEF 100 U/ML IJ NOVO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin ultralente (0.4 IU/kg)
Study: 14615229
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of different analysis methods
Study: 26245776
Drug: Clobazam (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (medium and high dosage)
Study: 26245776
Drug: Clobazam (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (low dosage)
Study: 23384975
Drug: Compounded estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounded estrogen cream (Bi‐est (80:20); 2.0 mg) + compounded oral progesterone 100 mg
Study: 23384975
Drug: Compounded estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounded estrogen cream (Bi‐est (80:20); 2.5 mg) + compounded oral progesterone 100 mg
Study: 23384975
Drug: Compounded estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compounded estrogen cream (Bi‐est (80:20); 3.0 mg) + compounded oral progesterone 100 mg
Study: 21279864
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg · kg(‐1) body weight) after a 4-day withdrawal period
Study: 21279864
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg · kg(‐1) body weight) without a withdrawal period
Study: 15621120
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1000 mg twice a day with stepwise reduction of CNI
Study: 15621120
Drug: Continue current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue current CNI dose
Study: 11273951
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg IM (Group K)
Study: 9678092
Drug: Low‐dose, gestodene‐containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐dose, gestodene‐containing triphasic oral contraceptive
Study: 8388583
Drug: Enoxaparin (EN)
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (EN) 40 mg
Study: 8388583
Drug: Enoxaparin (EN)
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (EN) 1 mg kg‐1
Study: 8388583
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH) 5,000 IU
Study: 28624553
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg daily for 8 weeks
Study: 28624553
Drug: Naftopidil 75
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 75 mg daily for 8 weeks
Study: 22516884
Drug: Horticultural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy (n = 37)
Study: 22516884
Drug: Pain-management program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-management program without horticultural therapy (control, n = 42)
Study: 8659720
Drug: Droperidol 2.5
Normalized name: droperidol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 2.5 mg with induction of anesthesia and 1.25 mg 12 h later (Group 2, n = 25)
Study: 8659720
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg with induction (Group 3, n = 25)
Study: 8659720
Drug: Ondansetron plus
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron plus droperidol at the same doses as Groups 3 and 2 (Group 4, n = 25)